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Abstract
Background: LCL161, a novel Smac mimetic, is known to have anti-tumor activity and improve chemosensitivity in
various cancers. However, the function and mechanisms of the combination of LCL161 and paclitaxel in non-small
cell lung cancer (NSCLC) remain unknown.
Methods: Cellular inhibitor of apoptotic protein 1 and 2 (cIAP1&2) expression in NSCLC tissues and adjacent
non-tumor tissues were assessed by immunohistochemistry. The correlations between cIAP1&2 expression and
clinicopathological characteristics, prognosis were analyzed. Cell viability and apoptosis were measured by MTT
assays and Flow cytometry. Western blot and co-immunoprecipitation assay were performed to measure the
protein expression and interaction in NF-kB pathway. siRNA-mediated gene silencing and caspases activity assays
were applied to demonstrate the role and mechanisms of cIAP1&2 and RIP1 in lung cancer cell apoptosis. Mouse
xenograft NSCLC models were used in vivo to determine the therapeutic efficacy of LCL161 alone or in
combination with paclitaxel.
Results: The expression of cIAP1 and cIAP2 in Non-small cell lung cancer (NSCLC) tumors was significantly higher
than that in adjacent normal tissues. cIAP1 was highly expressed in patients with late TNM stage NSCLC and a poor
prognosis. Positivity for both cIAP1 and cIAP2 was an independent prognostic factor that indicated a poorer
prognosis in NSCLC patients. LCL161, an IAP inhibitor, cooperated with paclitaxel to reduce cell viability and induce
apoptosis in NSCLC cells. Molecular studies revealed that paclitaxel increased TNFα expression, thereby leading to
the recruitment of various factors and the formation of the TRADD-TRAF2-RIP1-cIAP complex. LCL161 degraded
cIAP1&2 and released RIP1 from the complex. Subsequently, RIP1 was stabilized and bound to caspase-8 and FADD,
thereby forming the caspase-8/RIP1/FADD complex, which activated caspase-8, caspase-3 and ultimately lead to
apoptosis. In nude mouse xenograft experiments, the combination of LCL161 and paclitaxel degraded cIAP1,2,
activated caspase-3 and inhibited tumor growth with few toxic effects.
Conclusion: Thus, LCL161 could be a useful agent for the treatment of NSCLC in combination with paclitaxel.
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Background
Lung cancer is the leading cause of death for cancer pa-
tients in both males and females worldwide [1]. Non-
small cell lung cancer (NSCLC) accounts for more than
80 % of all lung cancers [2], and most patients are diag-
nosed at an advanced stage without the opportunity for
surgery. Paclitaxel, as a first-line chemotherapeutic drug,
has been shown to be effective in NSCLC treatment [3].
However, its curative effect is limited, and its side effects
are severe. Therefore, novel drug combinations with pac-
litaxel need to be explored to improve its curative effect
and reduce its side effects.
Inhibitor of apoptosis proteins (IAPs) play an import-
ant role in cell apoptosis, and they are widely expressed
in human tumor tissues [4]. cIAP1 and cIAP2, members
of the IAP family, indirectly regulate apoptosis by pre-
venting Smac for inhibiting XIAP-caspase interaction
and by preventing the formation of caspase-8-activating
platform. Besides, they have a really interesting new gene
(RING) domain in their C terminus that promotes self-
ubiquitination and ubiquitination of cIAP1 partners such
as RIP1, promoting the formation of signaling complex
leading to NF-kB activation [5, 6]. Genetic evidence has
shown that 11q21-23 (which encodes cIAP1 and cIAP2)
is a potential proto-oncogene, and the high expression
of cIAP1 and cIAP2 has been closely related to che-
moresistance and poor prognosis [7]. Consequently,
cIAP1 and cIAP2 are likely to be therapeutic targets with
promising potential.
Second mitochondrial-derived activator of caspases
(Smac) is a significant endogenous antagonist of IAPs [8].
Smac mimetics are artificially synthesized small-molecule
compounds that mimic the apoptotic function of Smac
[5]. Previous studies have shown that Smac mimetics in-
duce cell apoptosis by activating caspases [9, 10]. In the
past few years, an increasing number of studies have sug-
gested that the function of Smac mimetics in inducing cell
apoptosis is inseparably associated with the nuclear factor-
kappaB (NF-kB) pathway [11]. For example, the Smac mi-
metic AEG40730 releases NF-kB inducing kinase (NIK)
and activates the non-canonical NF-kB pathway through
inducing cIAP autoubiquitination, which causes tumour
necrosis factor-α (TNF-α) autocrine signaling and acti-
vates TNFR1, leading to apoptosis [12]; BV-6, another
Smac mimetic, restrains the canonical NF-kB pathway
by degrading cIAP, stabilizing receptor-interacting
protein 1 (RIP1) and forming the RIP1-FADD-caspase
8 complex, ultimately activating the death receptor
apoptotic pathway [13]. In lung cancer treatment, the
sensitivity of NSCLC cell lines to Smac mimetic,
Compound 3/4, alone is related to autocrine-secretion
of TNFα and the formation of RIP1-dependent
caspase-8-activating complex [14]. However, Smac mi-
metic, JP1201, could sensitize nonresponsive NSCLC
cell lines to standard chemotherapy independently of
TNF-α secretion [15].
LCL161, a novel Smac mimetic, has been tested as an
anticancer agent in phase I and phase II clinical trials. It
possesses many advantages such as good tolerability, low
toxicity and oral availability [16]. Recently, the anti-
proliferative effect of LCL161 was confirmed in some
solid tumors. For example, LCL161 sensitized radiother-
apy through inhibiting the expression of cIAP1, activat-
ing caspase-8 and leading to apoptosis in esophageal
cancer cells [17]. In liver cancer cells, LCL161 improved
the sensitivity of paclitaxel to drug-induced cell death, and
inhibition of Bcl-2 reversed LCL161 resistance [18, 19].
However, there are no reports of the use of LCL161 in
lung cancer. Therefore, we investigated use of LCL161
alone and in combination with paclitaxel in lung cancer
both in vitro and in vivo.
In this study, we found that the combination of
LCL161 and paclitaxel inhibited tumor growth both in
vitro and in vivo. Paclitaxel induced cell apoptosis by ac-
tivating caspase-8 and caspase-3. When LCL161 was
combined with paclitaxel, it degraded cIAP1 and cIAP2,
which are highly expressed in NSCLC patients and con-
fer a poor prognosis, and it resulted in the release of
RIP1 from the TRADD-TRAF2-RIP1-cIAP complex,
leading to the formation of the RIP1-FADD-Caspase-8
complex. Subsequently, caspase-8 and caspase-3 were
activated, ultimately leading to cell apoptosis.
Methods
Patients and samples
All specimens were collected from 126 NSCLC patients
(IA-IIIA; 32 females and 94 males; age range: 33–79
years) who underwent pulmonary surgery between
October 2006 and December 2009 at the First Affiliated
Hospital of Xi’an Jiaotong University (Xi’an, China). Clin-
icopathological data, including gender, age, histology, tumor
differentiation, tumor location, tumor size, lymph node me-
tastasis, pTNM stage and overall survival, were collected
for all cases. All patients had a single tumor without distant
metastasis, and none of them had previously been treated
with chemo- or radiotherapy. The study was approved by
the Ethics Committee of the First Affiliated Hospital of
Xi’an Jiaotong University, based on the patients’ written in-
formed consent for the usage of the biologic material.
Immunohistochemistry staining
Tumor specimens were fixed with 10 % formaldehyde
and embedded in paraffin blocks. Sections (4 μm) were
deparaffinized with xylene, rinsed and rehydrated
through a graded series of alcohols. Hematoxylin and
eosin staining was used to confirm the original histo-
pathological diagnosis. For immunohistochemistry, the
slides were treated with 3 % H2O2 for 10 min and then
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immersed in 0.01 M citrate buffer (pH 6.0) for 3 min in
a pressure cooker at 125 °C. After washing with PBS, the
slides were incubated with diluted primary antibody
(anti-cIAP1, cIAP2, and active caspase-3 from Abcam,
Cambridge, UK, and anti-Ki67 from Cell Signaling Tech-
nology, MA, USA) at 4 °C overnight and IgG/HRP
secondary antibody (1:250; Beijing Biosynthesis Inc.,
Beijing, China) for 30 min at room temperature. The re-
action was developed using a DAB chromogen solution.
Counterstaining was performed with hematoxylin before
dehydration and mounting. Staining reactions were de-
termined by microscopic examination. Both the intensity
and extent of staining were considered when analyzing
the data. The extent of staining was scored from 0 to
100 % (1 indicates 1–25 %, 2 indicates 26–50 %, 3 indi-
cates 51–75 %, 4 indicates 76–100 %), and the intensity
of staining was scored from 0 to 2 (0 indicates none; 1
indicates weak to moderate; 2 indicates strong). The
IHC score was determined as follows: high expression
(+): score ≥ 3; low expression (−): score ≤ 2.
Cell culture, drug treatment and transfection
The human cell lines A549 and H460 were purchased
from American Type Culture Collection (ATCC, VA,
USA). All cell lines were cultured in DMEM+ 10 % FBS
(GE Healthcare Life Sciences, UT, USA) at 37 °C in a
humidified atmosphere consisting of 5 % CO2 and 95 %
air. For drug treatment, cells were seeded into 6- to 96-
well plates and treated with a range of concentrations of
LCL161 and/or paclitaxel (Sigma, MO, USA) before de-
tection. The siRNAs for cIAP1,2 or RIP1 and the control
siRNAs were designed and produced by the Shanghai
GenePharma Co., Ltd (Shanghai, China). The siRNAs or
control siRNAs were transfected into NSCLC cells with
Lipofectamine 2000 (Invitrogen Life Technologies, CA,
USA). Western blotting was used to identify protein
knockdown in cells.
Cell viability assay (MTT)
Cell viability was determined by the MTT assay. Cells
(104 cells/well) were seeded in 96-well plates with 200 μl
of DMEM containing 10 % FBS. After 24 h, the cells
were exposed to LCL161 and/or paclitaxel at different
concentrations for 48 h. Next, 20 μl of MTT was added
per well at 37 °C for 4 h. The purple formazan crystals
were dissolved in 200 μl of DMSO. After 15 min, the ab-
sorbance was measured at 490 nm with a microplate
reader (Bio-Rad Laboratories, CA, USA).
Apoptosis assay
Apoptosis was determined using an apoptosis detection
kit (BD Biosciences, NJ, USA). After washing with PBS,
106 cells were resuspended in 100 μl binding buffer,
followed by incubation with 5 μl FITC-Annexin V and
5 μl PI for 20 min at room temperature in the dark.
Next, 400 μl of binding buffer was added, and flow cy-
tometry was performed using a FACScan flow cytometer
(BD Biosciences).
Caspase-8 and caspase-3 activity assays
Cells were washed with PBS and resuspended in lysis buf-
fer on ice for 15 min. After centrifugation, the supernatants
were collected and the caspase-8 and caspase-3 activities
were measured using the Caspase-8 Activity Assay Kit and
the Caspase-3 Activity Assay Kit (Beyotime, Shanghai,
China) according to the manufacturer’s instructions. The
working principle of this kit is based on the cleavage of the
caspase-8 substrate, Ac-IETD-pNA, and the caspase-3 sub-
strate, Ac-DEVD-pNA. The release of p-nitroanilide (pNA)
was qualified by determining the absorbance at 405 nm
using a microplate reader. Caspase-8 and caspase-3 activ-
ities were expressed relative to control cells.
Western blot and Co-immunoprecipitation assay
Western blot and co-immunoprecipitation assay were per-
formed as described previously [20] using the following
antibodies: Survivin, anti-FADD, pro-caspase-8 (Santa
Cruz Biotechnology, CA, USA), XIAP (Epitomics, CA,
USA), cleaved Caspase-8, TNFα, TRAF2, TRADD (Cell
Signaling Technology). cIAP1, cIAP2, RIP1, TNFR1 and
cleaved Caspase-3 and β-Actin (Abcam, Cambridge, UK)
was used as a loading control. Proteins were detected
using ECL detection (Thermo scientific, MA, USA). All
western blot data shown are representative of at least
three independent experiments.
Enzyme Linked Immunosorbent Assay (ELISA)
The media for H460 and A549 cell cultures were collected
24 h after the paclitaxel treatment. The level of TNFα in
the cell culture media was quantified using the Human
TNFα ELISA Kit (Beijing Biosynthesis Inc., Beijing, China)
in accordance with the manufacturer’s instructions and
measured at 450 nm in a microplate reader.
Nude mouse xenograft studies
Four-week-old BALB/c (athymic) nude mice were pur-
chased from the Center of Laboratory Animals of Xi’an
Jiaotong University and were bred under specific-
pathogen-free conditions. All animal experiments were
approved by the Ethics Committee of the First Affiliated
Hospital of Xi’an Jiaotong University. A total of 5 ×
106 H460 cells were subcutaneously injected into the right
flank of nude mice. When the average tumor volume
reached 100 mm3, the mice were randomly divided into 4
groups. We treated the mice with 10 mg/kg LCL161 and/
or 20 mg/kg paclitaxel through intraperitoneal injection
every two days for three weeks. The tumor size and body
weight were recorded with a caliper using the following
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formula: tumor volume = length × width × width/2. One
week later, the mice were sacrificed, and solid tumors were
removed for further analyses.
Statistical analysis
The results are presented as the mean values ± SD. Pearson
chi-squared and Fisher’s exact tests were used to compare
frequencies. The correlation between the expression of
cIAP1 and cIAP2 was evaluated by Spearman correlation
analysis. Kaplan–Meier analysis was used to produce sur-
vival curves with differences tested between groups by the
log-rank test. Univariate and multivariate analyses were
performed with the Cox regression model. Statistical sig-
nificance was assessed by two-tailed Student’s t test. Statis-
tical analyses were performed using SPSS version 13.0
(SPSS, Chicago, IL, USA). P < 0.05 was considered to indi-
cate a statistically significant result.
Results
cIAP1 and cIAP2 expression in NSCLC and para-tumor
tissues
Immunohistochemistry was performed to characterize
the expression of cIAP1 and cIAP2 in 126 NSCLC tis-
sues and 102 para-tumor tissues. The results showed
that, in the NSCLC tissues, cIAP1 was usually identified
in both the cytoplasm and nucleus, while cIAP2 was
identified only in the cytoplasm (Fig. 1). Of the 126 pa-
tients, tumors from 82 (65.1 %) were positive for cIAP1,
and tumors from 58 (46.0 %) were positive for cIAP2. Of
the 102 para-tumor tissues, 16 (15.7 %) were positive for
cIAP1, and 19 (18.6 %) were positive for cIAP2. The ex-
pression of cIAP1 and cIAP2 in NSCLC was significantly
higher than that in the para-tumor tissues (P < 0.001)
(Table 1). Tumors from 31 (24.6 %) patients expressed
high levels of cIAP1 and low levels of cIAP2. Tumors
from 7 (5.6 %) patients expressed low levels of cIAP1
and high levels of cIAP2. Tumors from 51 (40.5 %) pa-
tients expressed high levels of both cIAP1 and cIAP2,
whereas tumors from 37 (29.4 %) patients expressed low
levels of both proteins. Moreover, a positive correlation
was found between cIAP1 and cIAP2 expression in
NSCLC (rs = 0.443, P < 0.001) (Table 2).
cIAP1/cIAP2 expression and clinicopathological
characteristics
The contingency table analysis was used to examine the
correlation between cIAP1/cIAP2 expression and clini-
copathological characteristics in NSCLC patients. The
Fig. 1 The expression of cIAP1 and cIAP2 in NSCLC and para-tumor tissues by immunohistochemistry. The positive expression of cIAP1 (a) and
cIAP2 (d) in para-tumor tissues. The positive (b) and negative (c) expression of cIAP1 in NSCLC tissues. The positive (e) and negative (f) expression
of cIAP2 in NSCLC tissues. Original magnification, ×200
Table 1 Comparison of cIAP1, cIAP2 expression in NSCLC and para-tumor tissues
Variable n c-IAP1 P c-IAP2 P
(%) Negative Positive Negative Positive
NSCLC 126 44(34.9) 82(65.1) <0.001 68(54.0) 58(46.0) <0.001
para-tumor 102 86(84.3) 16(15.7) 83(81.4) 19(18.6)
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associations between clinicopathological variables and
cIAP1/cIAP2 expression are shown in Table 3. Positive
cIAP1 expression was found to be significantly associ-
ated with pTNM stage (P = 0.025) but not with gender,
age, histology, tumor differentiation, tumor location,
tumor size, or lymph node metastasis (P > 0.05). How-
ever, there was no significant association between cIAP2
and any parameter (P > 0.05).
Prognostic value of cIAP1 and cIAP2 expression
Associations between cIAP1/cIAP2 expression and over-
all survival were evaluated by Kaplan–Meier survival
curves and the log-rank test. The patients whose tumors
were positive for cIAP1 had a significantly longer overall
survival than those whose tumors were negative for cIA-
P1(Log-rank = 4.378, P = 0.036) (Fig. 2a). However, the
prognosis of patients whose tumors were positive for
cIAP2 did not differ from those who were cIAP2 negative
Table 2 Correlation of cIAP1 and cIAP2 expression in NSCLC
c-IAP2 r P value
Negative Positive
c-IAP1
Negative 37(29.4) 7(5.6) 0.443 <0.001
Positive 31(24.6) 51(40.5)
Table 3 Correlation between cIAP1, cIAP2 expression and clinicopathological characteristics
Variable n c-IAP1 P c-IAP2 P
Negative Positive Negative Positive
Gender
Male 94 32 62 0.723 50 44 0.764
Female 32 12 20 18 14
Age
≤ 65 79 28 51 0.873 44 35 0.614
> 65 47 16 31 24 23
Histology
Squamous cell carcinoma 51 19 32 0.661 30 21 0.665
Adenocarcinoma 59 21 38 30 29
Others 16 4 12 8 8
Tumor differentiation
G1 15 7 8 0.591 8 7 0.176
G2 67 22 45 41 26
G3 44 15 29 19 25
Tumor location
central type 69 24 45 0.971 40 29 0.321
peripheral type 57 20 37 28 29
Tumor size
T1 32 13 19 0.423a 22 10 0.074a
T2 77 28 49 39 38
T3 14 3 11 7 7
T4 3 0 3 0 3
Lymph node metastasis
N0 74 30 44 0.126 44 30 0.115
N1 29 10 19 16 13
N2 23 4 19 8 15
pTNM stage
I 57 26 31 0.025* 34 23 0.084
II 43 14 29 25 18
III 26 4 22 9 17
Total 126 44 82 68 58
aFisher’s exact tests; *p < 0.05
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(Log-rank = 2.396, P = 0.122) (Fig. 2b). To better evaluate
the prognostic value of cIAP1 and cIAP2 expression, the
OS of patients whose tumors were positive for both cIAP1
and cIAP2 (cIAP1+/cIAP2+) was evaluated. This group
demonstrated a significantly shorter OS than the rest
of the patients (cIAP1-/cIAP2+, cIAP1+/cIAP2-, and
cIAP1-/cIAP2- combined; Log-rank = 10.29, P = 0.001),
and this difference was much more obvious compared to
the OS differences between patients who were positive or
negative for cIAP1 or cIAP2 alone (cIAP1+ vs. cIAP1-,
P = 0.036; cIAP2+ vs. cIAP2-, P = 0.122) (Fig. 2c).
In univariate analysis based on the Cox regression
model, we analyzed the predictive value of cIAP1 and
cIAP2 expression, as well as that of other clinicopatho-
logical characteristics, including gender, age, and hist-
ology. The results indicated that tumor size, lymph node
metastasis, pTNM stage, cIAP1 expression, and cIAP1+/
cIAP2+ were good predictors of OS for NSCLC patients
(Table 4). The pTNM stage of NSCLC is dependent on
tumor size and lymph node metastasis; therefore, we an-
alyzed other predictive factors, including tumor size,
lymph node metastasis and cIAP1. cIAP1 was not an in-
dependent predictive factor for the prognosis of NSCLC.
In multivariate Cox regression analysis by tumor size,
lymph node metastasis and cIAP1+/ cIAP2+, the results
revealed that cIAP1+/ cIAP2+ has a relative risk of 1.625
for OS, with P = 0.029 (Table 5).
Taken together, cIAP1 expression is an independent
factor that can be used to evaluate prognosis in NSCLC
patients, with cIAP1 expression predicting a poorer
prognosis, especially in patients whose tumors are posi-
tive for cIAP2.
LCL161 and paclitaxel synergistically reduce cell viability
and induce cell apoptosis in NSCLC cells
The antiproliferative effects of LCL161 and paclitaxel
were evaluated by MTT assays. A549 and H460 cells
were treated with 0–200 μM LCL161 or paclitaxel for
48 h. Cells viability was reduced prominently with pacli-
taxel treatment but not with LCL161 treatment (Fig. 3a,
b). When cells were treated with a combination of 0–
10 μM LCL161 and 0–20 μM paclitaxel, the cell viability
was lower than with paclitaxel treatment alone (Fig. 3c).
Additionally, cells treated with 10 μM LCL161 and/or
10 μM paclitaxel for 6–72 h showed time-dependent via-
bility (Fig. 3d). To further study the apoptotic effects of
the combination, we treated cells with 10 μM LCL161
and/or 10 μM paclitaxel for 48 h, and cell apoptosis was
measured by Annexin V/PI analysis. Consistent with the
results of the MTT assay, cell apoptosis in the LCL161/
paclitaxel co-treatment group was significantly decreased
compared with that in cells treated with LCL161 or pacli-
taxel alone (P < 0.05, Fig. 4a, b).
Paclitaxel increases TNFα secretion, and LCL161 decreases
the expression of cIAP1 and cIAP2
It has been reported that Smac mimetics induce TNFα-
dependent cancer cell death by targeting IAPs. To inves-
tigate whether paclitaxel promotes LCL161-induced
apoptosis via TNFα, western blotting was performed
Fig. 2 Association between the expression of cIAP1 or cIAP2 and the survival of patients with NSCLC. Overall survival was plotted as a function of
a cIAP1 expression (log rank, P = 0.036), b cIAP2 expression (log rank, P = 0.122), and c cIAP1 and cIAP2 expression (log rank, P = 0.001). Analysis
was performed by the Kaplan–Meier method. The log-rank test was used to compare survival curves
Table 4 Univariate Cox regression analysis of overall survival in
NSCLC patients
Variable HR 95 % CI P-value
Gender 0.93 0.578–1.497 0.765
Age 0.968 0.628–1.493 0.884
Histology 1.015 0.747–1.379 0.926
Tumor differentiation 1.275 0.923–1.763 0.141
Tumor location 1.008 0.662–1.536 0.97
Tumor size 1.684 1.180–2.404 0.004*
Lymph node metastasis 1.891 1.460–2.451 <0.001*
pTNM stage 2.141 1.630–2.811 <0.001*
cIAP1 1.623 1.024–2.572 0.039*
cIAP2 1.388 0.912–2.111 0.126
cIAP1+/ cIAP2+ 1.965 1.287–3.000 0.002*
HR hazard ratio, CI confidence interval, *p < 0.05
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Table 5 Multivariate Cox regression analysis of overall survival in NSCLC patients
Variable B SE Wald P-value HR 95 % CI
Tumor size 0.359 0.183 3.858 0.050 1.432 1.001–2.049
Lymph node metastasis 0.545 0.135 16.160 0.000* 1.724 1.322–2.248
cIAP1 0.331 0.238 1.933 0.164 1.393 0.873–2.222
Tumor size 0.328 0.183 3.209 0.073 1.388 0.970–1.986
Lymph node metastasis 0.530 0.135 15.300 0.000* 1.698 1.302–2.215
cIAP1+/ cIAP2+ 0.485 0.222 4.792 0.029* 1.625 1.052–2.510
B partial regression coefficient, S.E. standard error of partial regression coefficient, Wald X2 value which was used to compare if there was difference between total
partial regression coefficient and 0, HR hazard ratio, CI confidence interval, *p < 0.05
Fig. 3 LCL161 and paclitaxel synergize to reduce cell viability in NSCLC cells. A549 and H460 lung cancer cells were treated for 48 h with the
indicated concentrations of LCL161 (a) or paclitaxel (b). Cells were treated for 48 h with the indicated concentrations of LCL161 and paclitaxel (c)
or for the indicated times with 10 μM LCL161 and/or 10 μM paclitaxel (d). Cell viability was determined by the MTT assay. Data are represented
as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001
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after cells were treated with 0–10 μM paclitaxel alone
for 48 h. The expression of TNFα increased coincident
with the activation of caspase-8 and caspase-3 during
paclitaxel treatment (Fig. 5a). In addition, for quantifica-
tion of secreted TNFα, supernatants were collected after
treatment with paclitaxel and analyzed by ELISA. Pacli-
taxel treatment increased TNFα secretion in lung cancer
cells (Fig. 5b). Besides, cells were treated with 0–10 μM
LCL161 alone for 48 h, and IAPs were detected by west-
ern blotting. The expression of XIAP and Survivin did
not change, whereas that of cIAP1 and cIAP2 was sig-
nificantly decreased (P < 0.01, Fig. 5c). Additionally, we
used siRNA to knockdown cIAP1 and cIAP2 and then
treated the cells with paclitaxel. The knockdown of
cIAP1 and cIAP2 was verified by western blotting
(Fig. 6a, b). As expected, the paclitaxel-induced apop-
tosis was significantly increased after knockdown of
cIAP1 and cIAP2 (P < 0.05, Fig. 6c).
LCL161 and paclitaxel cooperate to activate caspase-3
and caspase-8
We used caspase activity assays to further confirm the
function of caspase-3 and caspase-8 in apoptosis induced
by LCL161/paclitaxel co-treatment. The co-treatment sig-
nificantly increased caspase-3 and caspase-8 activity in
both A549 and H460 cells (P < 0.01, Fig. 7a, b). To con-
firm whether caspase-8 activation is indispensable in cell
apoptosis induced by LCL161 and paclitaxel, we used the
caspase-8 inhibitor Z-IETD-FMK. The addition of Z-
IETD-FMK significantly inhibited caspase-8 activation
and decreased cell apoptosis during LCL161/paclitaxel
co-treatment (P < 0.05, Fig. 7c, d). These experiments
demonstrated that LCL161 and paclitaxel cooperate
to trigger caspase-8 and caspase-3 activation, thereby
inducing apoptosis.
RIP1 is a critical mediator of LCL161/paclitaxel-induced
apoptosis
As Smac mimetics have been shown to release RIP1
from the TRADD-TRAF2-RIP1-cIAP complex, we
assessed the changes in the levels of these proteins
during treatment with paclitaxel and/or LCL161. Pacli-
taxel decreased the expression of cIAP1 but not TRADD,
TRAF2, RIP1 and cIAP2. However, LCL161 accelerated
the degradation of cIAP1 and cIAP2, whereas it led to the
















   
   
   
   




















Fig. 4 LCL161 and paclitaxel synergistically induce cell apoptosis in NSCLC cells. a A549 and H460 lung cancer cells were treated with 10 μM
LCL161 and/or 10 μM paclitaxel for 48 h. Annexin V/PI staining was used to detect apoptosis. b Statistical analysis of the proportion of lung
cancer cells in different periods. Data are represented as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001
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Fig. 5 (See legend on next page.)
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TNFR1 was increased during treatment with paclitaxel
and/or LCL161 (Fig. 8a). Furthermore, using co-
immunoprecipitation, we found that RIP1 directly inter-
acted with TRADD, TRAF2 and cIAP in the presence of
paclitaxel treatment and that RIP1 was released from the
complex during LCL161/paclitaxel co-treatment (Fig. 8b).
Next, we assessed whether the formation of the
RIP1-FADD-Caspase-8 complex, after RIP1 release
from the TRADD-TRAF2-RIP1-cIAP complex, caused
caspase-8 activation. We used anti-caspase-8 antibody to
co-immunoprecipitate caspase-8 and detected its inter-
action with FADD and RIP1 in A549 cells. As expected,
caspase-8 directly interacted with RIP1 and FADD in the
presence of LCL161 with or without paclitaxel (Fig. 8c).
To investigate the requirement for RIP1 in LCL161/
paclitaxel-induced apoptosis in A549 cells, we transi-
ently silenced RIP1 with a small interfering RNA and
treated cells with 10 μM LCL161 and/or 10 μM pacli-
taxel for 24 h, followed by staining with propidium
iodide and FITC-Annexin V to assess apoptosis by flow
cytometry. In the RIP1 knockdown A549 cells, LCL161/
paclitaxel-induced apoptosis was significantly attenuated
compared with that in control cells treated with the
same drugs (P < 0.01, Fig. 8d, e). Together, this set of
experiments demonstrates that RIP1 is a critical medi-
ator of LCL161/paclitaxel-induced caspase-8 activation
and apoptosis.
The combination of LCL161 and paclitaxel inhibits tumor
growth by degrading cIAP1 and cIAP2 and activating
caspase-3 in vivo
We next sought to determine whether LCL161 and pac-
litaxel affect tumor growth, by using an H460 subcuta-
neous tumor model. Representative images of xenografts
from mice treated with LCL161 and/or paclitaxel for
three weeks are shown in Fig. 9a. Compared with the
control group, the tumor volume was smaller following
treatment with LCL161 or paclitaxel (P < 0.001, Fig. 9b).
(See figure on previous page.)
Fig. 5 Paclitaxel increases TNFα expression, and LCL161 decreases cIAP1 and cIAP2 expression. a A549 and H460 cells were treated for 48 h with
0–10 μM paclitaxel. The protein levels of TNF-α and cleaved caspase-8 and cleaved caspase-3 were assessed by western blotting. b Cells were
treated for 24 h with 0–10 μM paclitaxel. The level of TNFα in the cell culture media was quantified using the Human TNFα ELISA Kit. c A549 and
H460 cells were treated for 48 h with 0–20 μM LCL161. The protein levels of cIAP1, cIAP2, XIAP and survivin were assessed by western blotting.
β-actin was used as a loading control. The bar graphs represent the mean ± SD of different proteins/β-actin; *P < 0.05; **P < 0.01; ***P < 0.001
Fig. 6 The knockdown of cIAP1 and cIAP2 increases paclitaxel-induced cell apoptosis. a A549 and H460 cells were transfected with siRNA control
or siRNA cIAP1,2 for 48 h. The expression of cIAP1,2 was assessed by western blotting. β-Actin was used as a loading control. b The bar graphs
represent the mean ± SD of cIAP1 or cIAP2/β-actin. c After transfection with siRNA for 48 h, the cells were treated for 48 h with 10 μM paclitaxel,
and their apoptosis was detected by Annexin V/PI staining. Data are represented as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001
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Additionally, the drug combination manifested much
better antitumor activity than either LCL161 or pacli-
taxel alone (P < 0.001, Fig. 9b). Furthermore, there was
no prominent weight loss in mice treated with LCL161,
paclitaxel, or the combination (P > 0.05, Fig. 9c).
We performed H&E staining to verify tumor tissues
and immunohistochemistry to detect the expression of
cIAP1, cIAP2, caspase-3 and Ki-67 in the xenografted
tissues (Fig. 10a). As expected, LCL161 significantly
down-regulated cIAP1 and cIAP2 and activated caspase-
3 in vivo (p < 0.05), especially in the groups that received
the drug combination (p < 0.01, Fig. 9b). Decreased ex-
pression of Ki-67 was observed in the LCL161 and pacli-
taxel co-treatment group, indicating that tumor cell
proliferation was significantly inhibited by drugs co-
treatment (p < 0.01, Fig. 10b). Taken together, these data
indicate that the combination of LCL161 and paclitaxel
inhibits tumor growth by degrading cIAP1 and cIAP2
and activating caspase-3 in a NSCLC xenograft model.
Discussion
IAPs are highly expressed in numerous tumor tissues
and their levels are closely related to the prognosis of
patients [7, 8]. The overexpression of cIAP1 in bladder
cancer, cervical cancer, and head and neck tumors
indicates a poor prognosis, while the overexpression of
cIAP2 is a biomarker for the early advanced stage of
pancreatic cancer [21–23]. In lung cancer studies,
expression of cIAPl and cIAP2 was correlated but they
didn’t predict response to chemotherapy [24]. cIAPl
mRNA expression was elevated in patients with adeno-
carcinoma, especially in low TMN adenocarcinomas
[25]. cIAP2 were increased in more advanced grades of
bronchial IEN lesions than in normal bronchial
Fig. 7 LCL161 and paclitaxel cooperate to activate caspase-3 and caspase-8. A549 and H460 cells were treated for 24 h with 10 μM LCL161
and/or 10 μM paclitaxel. The changes in caspase-8 (a) and caspase-3 (b) activity were determined as described in the Materials and Methods
section. Data are provided as mean ± SD, *P < 0.05; **P < 0.01; ***P < 0.001. c NSCLC cells were treated for 24 h with the combination of 10 μM
LCL161 and 10 μM paclitaxel in the presence or absence of 20 μM caspase-8 inhibitor Z-IETD-FMK. Caspase-8 activity was detected using a
caspase-8 activity assay kit. d Annexin V/PI staining was used to detect apoptosis, and the apoptotic rates were provided as mean ± SD;
*P < 0.05; **P < 0.01; ***P < 0.001
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epithelium [26]. In this study, we demonstrated that the
expression of cIAP1 and cIAP2 in resectable NSCLC
was higher than that in adjacent normal tissues. cIAP1
was highly expressed in patients with late TNM stage
and a poor prognosis, but the P-value (0.036) was only
slightly lower than 0.05. When analyzing the prognosis
by combining cIAP1 with cIAP2, we found that the
prognosis was even worse in patients with high expres-
sion of both cIAP1 and cIAP2, and the P-value was less
than 0.001 compared with the rest of patients.
Therefore, it was more effective to evaluate prognosis by
combining cIAP1 with cIAP2, possibly because cIAP1
and cIAP2 have similar structures and therefore a simi-
lar capacity to inhibit apoptosis, and it was more difficult
to induce cell apoptosis if both of these were highly
expressed. Actually, more than forty percent of tumor
expressed a high level of both cIAP1 and cIAP2. It
probably because a potential proto-oncogene, 11q21-23,
encodes both cIAP1 and cIAP2, and expresses high in
tumor tissues [7]. Besides, some studies revealed that
Fig. 8 RIP1 is a critical mediator of LCL161-induced apoptosis. a A549 cells were treated for 48 h with 10 μM paclitaxel with/without 10 μM
LCL161, and western blotting was performed for TRADD, TRAF2, RIP1, TNFR1, cIAP1 and cIAP2. b A549 cells were treated with 10 μM paclitaxel
with/without 10 μM LCL161 for 48 h, and 5 μM proteasome inhibitor MG132 for 4 h before collecting the cells. Anti-RIP1 antibody was used to
co-immunoprecipitate RIP1 and detected its interaction with TRADD, TRAF2 and cIAP. c A549 cells were treated for 48 h with 10 μM LCL161
and/or 10 μM paclitaxel in the presence of 20 mM Z-IETD-FMK. Caspase-8 was immunoprecipitated using an anti-caspase-8 antibody. The detection
of RIP1 and FADD proteins was performed by western blot analysis. d A549 cells were transiently transfected with siRNA sequences against RIP1 for
48 h and then were treated with 10 μM LCL161 and/or 10 μM paclitaxel for another 48 h. RIP1 expression was analyzed by western blotting 48 h post-
transfection. e Annexin V/PI staining was used to detect apoptosis, and the apoptotic rates are provided as mean ± SD; *P< 0.05; **P< 0.01; ***P< 0.001
Yang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:158 Page 12 of 17
nuclear expression of cIAP1 was strongly correlated to
poor patient prognosis in bladder cancer and head and
neck squamous cell carcinomas [21, 27]. The function of
nuclear cIAP and the mechanism of its degradation
under treatment with Smac mimetics are still unknown.
So, it could be interesting to quantify and analyze the
nuclear cIAP in NSCLC patients and try to explore its
mechanisms under treatment with Smac mimetics in the
future.
Many studies have shown that Smac mimetics can ac-
tivate caspases and the apoptotic pathway by degrading
IAPs, especially cIAP1 and cIAP2, leading to apoptosis
Fig. 9 The combination of LCL161 and paclitaxel has strong antitumor activity in vivo. Approximately 2 × 106 H460 cells were injected subcutaneously
into each nude mouse. After tumor formation, 10 mg/kg LCL161 and/or 20 mg/kg paclitaxel were intraperitoneally injected into the mice. a Typical
images of mice with H460 xenografts in the control, LCL161, paclitaxel and drug combination groups. Curves of tumor growth (b) and body weight (c)
for H460 xenografts with drug treatment. The tumor volume and body weight of the mice are provided as mean ± SD; *P< 0.05; **P< 0.01; ***P < 0.001
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[28, 29]. In our study, we demonstrated that LCL161 sen-
sitized paclitaxel by degrading IAPs. In addition, paclitaxel
increased the expression of TNFα and activated the ex-
ogenous apoptotic pathway, while LCL161 degraded IAPs,
activated caspase-8 in the pathway and induced cell apop-
tosis. The latter finding explains why the effect of LCL161
is not obvious when used alone but is very prominent in
combination with paclitaxel. This was also consistent with
other studies showing that Smac mimetics can induce
apoptosis when combined with TNFα [30, 31]. Further-
more, we knocked down cIAP1 and cIAP2 expression
with siRNA, sensitizing cells to paclitaxel-induced apop-
tosis. Additionally, the caspase-8 inhibitor Z-IETD-FMK
was able to inhibit apoptosis in cells co-treated with pacli-
taxel and LCL161. These results further show that the
two-drug combination induced cell apoptosis by degrad-
ing cIAP1 and cIAP2 and activating caspase-8, thereby in-
ducing the exogenous apoptotic pathway. It has been
shown that the caspase 8 inhibitor, FLIP, inhibited Smac
induced apoptosis and down-regulation of FLIP enhanced
Smac mimetic induced cell death [12, 32, 33]. Besides,
some other studies showed that FLIP was a target for pac-
litaxel/taxol induced apoptosis [34–36]. This is probably
another mechanism of LCL161 and paclitaxel combin-
ation induced cell apoptosis.
To further explore the mechanisms of LCL161- and
paclitaxel-induced apoptosis, we investigated RIP1 com-
plex to connect cIAP1/2 with caspase-8. We found that
paclitaxel promoted RIP1 binding to TRADD, TRAF2 and
cIAP1/2. When LCL161 was combined with paclitaxel,
cIAP1 and cIAP2 were degraded, but other proteins accu-
mulated. RIP1 (and also TRAF2) is ubiquitination targets
of cIAP1. cIAP1 can induce the conjugation of K63-
ubiquitin chains promoting the activation of NF-kB and
also K48-ubiquitin chain inducing proteasomal degrad-
ation of RIP1 (and TRAF2) [37, 38]. Thus, the upregulation
Fig. 10 The combination of LCL161 and paclitaxel inhibits cIAP1 and cIAP2 and activates caspase-3 in vivo. a The histology of tumor xenograft tissues
was confirmed using hematoxylin and eosin (H&E) staining. cIAP1, cIAP2, Ki67 and activated caspase-3 were detected by immunohistochemistry.
Original magnification, ×200. b Quantification of the ratio of the positive staining in each tumor tissue region, provided as mean ± SD; *P < 0.05;
**P < 0.01; ***P < 0.001
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of RIP1 (and TRAF2) could be related to an inhibition of
UPS-mediated degradation, because of cIAPs degradation.
On co-treatment with paclitaxel and LCL161, TNFα path-
way is activated and cIAPs are ubiquitinated, therefore,
RIP1 and TRAF2 were accumulated. However, the
Fig. 8 panel b showed that LCL161 treatment inhibits
RIP1, TRADD, TRAF2 and cIAP complex assembly in
cells in which the cIAP1&2 degradation is blocked by
MG132 (as shown in the input). Thus, the release of
RIP1 from the complex is not related to cIAP1&2
degradation. MG132 is a proteasome inhibitor, which
inhibited the degradation of cIAP1&2, but it did not
inhibit the ubiquitination of cIAP1&2. It is possibly
because the ubiquitination of cIAP1&2 will lead to
both degradation of cIAP1&2 and the release of RIP1
from the complex. Furthermore, we found that caspase-8
was activated through combining with RIP1 and FADD in
the presence of LCL161 and paclitaxel. Additionally, we
knocked down RIP1 with siRNA, revealing that RIP1 was
indispensable in LCL161/paclitaxel-induced apoptosis.
Therefore, we speculated that LCL161 decreased the self-
degradation of the TRADD/TRAF2/RIP1/cIAP1,2 com-
plex by accelerating the degradation of cIAP1 and cIAP2
and stabilizing RIP1 to form the caspase-8/RIP1/FADD
complex, which then induced apoptosis by activating
caspase-8 (Fig. 11).
At present, clinical trials of LCL161 and paclitaxel co-
treatment are under way for patients with breast cancer
[39]. It will be important to conduct an in vivo study to
clarify the effects of the drug combination before clinical
studies in lung cancer. In our present study, LCL161
and paclitaxel co-treatment prominently inhibited tumor
growth without causing weight loss in mice. Thus, the
therapeutic dose of the drug combination likely had few
toxic effects on the mice. Furthermore, immunohisto-
chemistry revealed that the drug combination degraded
cIAP1 and cIAP2, activated caspase-3 and reduced the
level of Ki67, findings that were in accordance with the
results in vitro.
Conclusions
In conclusion, co-treatment with LCL161 and paclitaxel
may become an important way to improve the efficacy
of paclitaxel, as well as to reduce the toxic effects of lung
cancer treatment. However, more studies should be per-
formed to further validate the function and mechanisms
of the combination of LCL161 and other chemothera-
peutics in different cancers, establishing a solid founda-
tion for future clinical studies.
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